Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr
Morepen Laboratories Limited has reported Consolidated financial results for the period ended September 30, 2023.
Morepen Laboratories has received US Food and Drug Administration (FDA) napproval for its anti-allergy drug Fexofinadine Hydrochloride that is nmarketed in India under the brand name Allegra, among others. nFexofinadine is the most widely used, second-generation antihistamine ndrug for the treatment of allergy symptoms and hay fever, the company nsaid in a statement.
Morepen Laboratories Ltd announced that the board has approved transfer of the point-of-care medical devices business into a wholly-owned subsidiary on a slump sale basis, which is expected to be completed on or before 31st March 2022, subject to receipt of requisite regulatory approvals and fulfillment of customary closing conditions.
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and New Delhi-based Morepen Laboratories, have announced the production of the test batch of the Russian Sputnik V coronavirus vaccine in an exclusive facility in Himachal Pradesh. The first batch will be shipped to the Gamaleya Center for quality control.
Morepen LaboratoriesnMorepen Labsnn71.500.60 (0.85%)nnRead more at:nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indias-morepen-manufactures-first-test-batch-of-russias-sputnik-v-vaccine-rdif/articleshow/84167817.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Morepen Laboratories on Monday has received a license to manufacture Hydroxychloroquine (HCQ) from State Drug Controller, (HP) last week for its Baddi plant in Himachal Pradesh and is working to commercialize the production of HCQ in both API as well as tablets form.
Share price of Morepen Laboratories surged over 8 percent intraday on April 21 after the company received license to manufacture Hydroxychloroquine (HCQ) from State Drug Controller, (HP) last week for its Baddi plant in Himachal Pradesh.
Morepen Laboratories Ltd has developed and added three drugs to its portfolio of active pharmaceutical ingredients (APIs) for sale in domestic and global markets. The three bulk drugs/APIs are rivaroxaban (Xarelto), vildagliptin (Galvus, Zomelis) and UDCA (ursodeoxycholic acid). While two products rivaroxaban and vildagliptin will augment the company's presence in the cardiac and diabetic segments respectively, the third product UDCA will cater to the liver segment.
Morepen LaboratoriesBSE 6.30 % today said the US health regulator has given approval to Montelukast Sodium, used in managing asthma symptoms and seasonal allergies, for sale in the US market.